Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

1. Genovese, M.C.
2. McKay, J.D.
3. Nasonov, E.L.
4. Mysler, E.F.
5. Da Silva, N.A.
6. Alecock, E.
7. Woodworth, T.
8. Gomez-Reino, J.J.